The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Summer 2022 RFP: Accelerating the Translation of Parkinson's Disease Therapies, 2022Developing an Inhibitor of Transglutaminase 2 as a Disease-modifying Treatment for Parkinson’s Disease
Study Rationale: Clumping of alpha-synuclein in the brain is a key pathological feature of Parkinson’s disease (PD) and is believed to lead to brain cell degeneration. Identifying factors that...
-
Research Grant, 2022Development of a Radiolabeled Tracer for Detecting Insoluble Protein Aggregates in Parkinson’s Disease
Study Rationale: Many neurodegenerative disorders are caused by a toxic buildup of insoluble protein aggregates. In Parkinson’s disease (PD), accumulation of alpha-synuclein contributes to the death...
-
Research Grant, 2022Monitoring Prodromal and De Novo Parkinson’s Disease (PRONOVO) Using Multi-modal Imaging
Study Rationale: Individuals with Parkinson’s disease (PD) display variable impairment of the brain and peripheral nervous system, suggesting that PD includes a range of subtypes. Yet the underlying...
-
Research Grant, 2022Development of PET Tracer for Imaging SV2C in Parkinson's Disease
Study Rationale: Cells in the brain uses molecules such as dopamine, the neurotransmitter that is depleted in people with Parkinson’s disease (PD), to transmit signals from one to another. The...
-
Expanding Biological Understanding of Parkinson's Disease, 2022Deep Phenotyping of Parkinson's Disease Relevant Mitochondrial and Autophagic Mechanisms in Human iPSC-derived Neural Cells
Study Rationale: The causes of Parkinson’s disease (PD) are not fully understood. However, impairment in the function of mitochondria, the powerhouses of the cell, and in autophagy, a process whereby...
-
Spring 2022 RFA: Therapeutic Pipeline Program Pre-Clinical, 2022Assessing the Effects of USP30 Inhibitors on the Removal of Damaged Mitochondria in Nerve Cells
Study Rationale: Mitochondrial dysfunction is extensively associated with genetic and sporadic forms of Parkinson’s disease (PD). Yet there are currently no clinical trials that specifically aim to...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.